Clinical trials: Hepatic Function
Hepatic Impairment
A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment
This is an open-label, single-dose study to evaluate the pharmacokinetics and safety of DBPR108 in subjects with mild or moderate hepatic impairment (HI) compared to the matched control subjects with normal hepatic function.
- Trial name
- NCT04859426
- Testing
- DBPR108 tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Hepatic Impairment
A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function
The primary objective of the trial is to evaluate the pharmacokinetics (PK) of AMG 133 after a single subcutaneous (SC) dose in participants with mild, moderate, or severe hepatic impairment compared to participants with normal…
- Trial name
- NCT07428525
- Testing
- AMG 133
- Where
- 5 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Amgen
Hepatic Impairment, Healthy Volunteers
A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function
A study to evaluate the amount of fostamatinib in the blood in subjects with impaired hepatic (liver) function compared with healthy volunteers with normal liver function.
- Conditions
- Hepatic Impairment, Healthy Volunteers, Pharmacokinetics, Amount of R406 in Blood
- Trial name
- NCT01222455
- Testing
- Fostamatinib
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pharmacokinetics, Hepatic Insufficiency
Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)
Evaluate the potential effect of hepatic or renal impairment on the pharmacokinetics, safety and tolerability of BAY 1841788 (ODM-201).
- Conditions
- Pharmacokinetics, Hepatic Insufficiency, Renal Insufficiency
- Trial name
- NCT02894385
- Testing
- BAY1841788
- Where
- 2 sites in Germany
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Bayer
Hepatic Impairment, Healthy
Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function
The purpose of this study is to assess the pharmacokinetic profile of bardoxolone methyl following a single oral dose of 20 mg bardoxolone methyl in subjects with mild, moderate, and severe hepatic impairment, as compared to…
- Trial name
- NCT01563562
- Testing
- Bardoxolone Methyl
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Biogen
Hepatic Impairment
Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment
To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral dose in subjects with moderate and severe hepatic impairment.
- Trial name
- NCT02873650
- Testing
- dabrafenib
- Where
- 4 sites in United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Chronic, Liver Fibrosis
An Observational Cohort Study Evaluating Fatty Liver Disease and Liver Fibrosis in Moderate to Severe Psoriasis
Main objectives and outcome measures. 1. Establish prevalence of and factors contributing to fatty liver disease and liver fibrosis in patients with psoriasis. Fatty liver disease diagnosed via ultrasound.
- Conditions
- Psoriasis Chronic, Liver Fibrosis, Fatty Liver, Non-alcoholic Fatty Liver Disease
- Trial name
- CORE (NCT02174367)
- Testing
- Transient elastography
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- King's College London
Oxidative Stress, Liver Dysfunction
N-Acetyl Cysteine Effect on Liver Function After Mitral Valve Replacement
This study aimed at the impact of the N-acetyl cysteine on the improvement of liver function subsequently on-pum mitral valve replacement.
- Trial name
- NAC (NCT06486805)
- Testing
- N acetyl cysteine, normal saline
- Where
- Egypt
- Volunteers
- 54 people
- Sponsor
- Kasr El Aini Hospital
Liver Dysfunction, Liver Insufficiency
An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function
This is an investigational study of experimental Medication BMS-986231 given to participants with weakened or damaged liver function.
- Conditions
- Liver Dysfunction, Liver Insufficiency, Hepatic Failure, Myocardial Failure
- Trial name
- NCT03515980
- Testing
- BMS-986231
- Where
- 4 sites in Hungary, Poland
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatic Insufficiency, Hepatic Impairment
A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)
Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (LDL-C) in a person's blood.
- Trial name
- NCT06575959
- Testing
- Enlicitide
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cirrhosis, Acute Liver Failure
Evaluation of Cardiac Function in Acutely Decompensated Cirrhosis
This project aims to investigate cardiac function in patients with cirrhosis in the acute setting. Acute decompensation and acute-on-chronic liver failure are major events in the life of a patient as they herald disease…
- Conditions
- Cirrhosis, Acute Liver Failure, Cardiomyopathies
- Trial name
- DYNACORD-AD (NCT05413083)
- Where
- Romania
- Volunteers
- 70 people
- Sponsor
- Clinical Hospital Colentina
Primary Hepatocellular Carcinoma
Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media
Primary Hepatocellular Carcinoma (PHC) is one of the most common malignant tumors in the world. In men is the fifth most frequently diagnosed cancer worldwide but the second most frequent cause of cancer death.
- Trial name
- NCT01563484
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Li Chen
Liver Cirrhosis, HCC - Hepatocellular Carcinoma
Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function
Splenectomy may relieve hypersplenism, reverse liver fibrosis, improve hepatic functional reserve, and reshape the systemic antitumor immune milieu by removing the source of negative immunomodulation.
- Conditions
- Liver Cirrhosis, HCC - Hepatocellular Carcinoma, Hypersplenism
- Trial name
- LHCS-HFRI (NCT07811687)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
Hepatitis B, Chronic
Optimal Time for Tenofovir Treatment of Anti-Hepatitis B Virus (HBV) During the Pregnancy
To determine the optimal time for the Tenofovir treatment of anti-Hepatitis B Virus (HBV) during the pregnancy among women with chronic HBV infection and high HBV DNA load.
- Trial name
- NCT02510963
- Testing
- Tenofovir Disoproxil Fumarate
- Where
- China
- Volunteers
- 300 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Non-Alcoholic Fatty Liver Disease
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content, cardiometabolic risk factors and gut microbiota…
- Trial name
- CARDIO-LIVER (NCT06704321)
- Testing
- TOTUM-448
- Where
- Canada
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Hepatic Insufficiency
A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems
This study is open to adults aged 18 years and older. People without liver problems and people who have mild or moderate liver problems can join the study.
- Trial name
- NCT05661344
- Testing
- BI 1015550
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Colorectal Cancer, Liver Metastasis Colon Cancer
The CLiFF Study: Change in Liver Function and Fat in Pre-operative Chemotherapy for Colorectal Liver Metastases
The CLiFF Study will assess changes in liver function and liver fat in patients with colorectal liver metastases (CLM) undergoing pre-operative chemotherapy before liver resection.
- Conditions
- Colorectal Cancer, Liver Metastasis Colon Cancer, Chemotherapy Effect, Obesity
- Trial name
- CLiFF (NCT03562234)
- Testing
- MR, LiMAx
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- University of Manchester
Subjects With Liver Function Injury, Normal Liver Function Subject
A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function
Evaluate the pharmacokinetic differences of the main metabolite 116-N1 of JT001 in subjects with mild and moderate liver function impairment and those with normal liver function, providing a basis for formulating clinical…
- Trial name
- NCT06093230
- Testing
- Deuremidevir Hydrobromide Tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
Non-Alcoholic Steatohepatitis
The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic Steatohepatitis
The term non-alcoholic fatty liver disease (NAFLD) is used to describe a range of chronic liver diseases that range from steatosis to steatohepatitis, advanced fibrosis, cirrhosis, or excessive alcohol consumption or other causes…
- Trial name
- NCT05065593
- Testing
- resistance and aerobic exercise, physical activity recommendation
- Where
- Turkey (Türkiye)
- Volunteers
- 26 people
- Sponsor
- Hacettepe University
Cancer
Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs
A retrospective cohort study using the LabRx medical claims database will be performed to address these objectives. The primary objective of this project is to examine the background rates of liver function test (LFT)…
- Trial name
- NCT01098500
- Testing
- Tyrosine kinase inhibitors
- Volunteers
- 3,800 people
- Sponsor
- GlaxoSmithKline